Setterwalls has advised Aptahem in connection with over-subscribed rights issue

Setterwalls has advised Aptahem AB in connection with a rights issue of units, consisting of shares and two series of warrants, that was subscribed to approximately 116 per cent.

Aptahem is a biotechnology company whose main business model is to, preclinically and clinically, develop aptamer-based pharmaceuticals for the treatment of life-threatening, acute, conditions in which coagulation and inflammation interact in the disease process. The company’s main pharmaceutical candidate, Apta-1, is being developed as an emergency drug with the aim of preventing the inflammatory response and thereby counteract the organ and tissue damage that, among other things, lead to the very high mortality of sepsis patients.

Through the rights issue, that was subscribed to approximately 116 per cent, Aptahem receives initial issue proceeds of approximately SEK 32.3 million before issue costs. In addition, Aptahem may receive additional issue proceeds of SEK 16.8–24 million before issue costs, and approximately SEK 9.6–13.2 million before issue costs, upon full exercise of all warrants that are issued in the rights issue.